Antidepressants and the FDA’s black-box warning: Determining a rational public policy in the absence of sufficient evidence

Virtual Mentor

Volumn 14, Issue 6, 2012, Pages 483-488

  Ho, Dien ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; RISK ASSESSMENT; SUICIDAL IDEATION; UNITED KINGDOM; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GREAT BRITAIN; HUMANS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; SUICIDAL IDEATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84882254852     PISSN: 19377010     EISSN: None     Source Type: Journal    
DOI: 10.1001/virtualmentor.2012.14.6.pfor2-1206     Document Type: Review

References (19)

1. Medicines and Healthcare products Regulatory Agency. Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depression disorder (MDD) in children and adolescents including summary of available safety and efficacy data. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019494?useSecondary=&show page=1. Accessed March 11, 2012.
2. Medicines and Healthcare products Regulatory Agency. Committee on safety of Medicines assessment report. http://www.mhra.gov.uk/home/groups/espolicy/documents/websiteresources/con014159.pdf; 2003: 49. Accessed March 11, 2012.
3. Emslie G, Kratochvil C, Vitiello B, et al. The Columbia Suicidality Classification Group, and the Tads Team. Treatment for Adolescents With Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 2006;45(12):1440-1455.
4. Medicines and Healthcare products Regulatory Agency Committee on the Safety of Medicine. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. http://www.mhra.gov.uk/home/groups/plp/documents/drugsafetymessage/con019472.pdf; 2004. Accessed March 11, 2012.
5. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):322-339.
6. Food and Drug Administration. Revisions to medication guide. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf; 2007. Accessed March 11, 2012.
7. Food and Drug Administration. Revisions to product labeling. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf; 2007. Accessed March 11, 2012.
8. Hammad, Laughren, Racoosin, 337.
9. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;163(11):1898-1904.
10. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41-47.
11. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012 Feb 9 [epub ahead of print].
12. March J, Silva S, Petrycki S, et al; Treatment for Adolescents with Depressions Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820.
13. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1696.
14. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003;290(8):1033-1041.
15. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2008;165(1):42-50.
16. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009;66(6):633-639.
17. Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ. Suicide trends among youths aged 10 to 19 years in the United States, 1996-2005. JAMA. 2008;300(9):1025-1026.
18. Waters R. Drug report barred by FDA:scientist links antidepressants to suicides in kids. San Francisco Chronicle. February 1, 2004. http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/02/01/MNGB64MJSP1.DTL&ao=all. Accessed March 11, 2012.
19. James W. William James: Writings 1878-1899. New York: Library of America; 1992.